Ivor Percent

2PUBLICATIONS
14CO-AUTHORS
Molecular targetsPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

|May 16, 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial.

Chung-Han Lee, Robert Motzer, Hamid Emamekhoo

|Apr 01, 2022
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer.

Christopher J Sweeney, Ivor J Percent, Sunil Babu

Pageof 1